SRNE
Price:
$0.006
Market Cap:
$3.31M
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti...[Read more]
Industry
Biotechnology
IPO Date
2007-01-19
Stock Exchange
NASDAQ
Ticker
SRNE
According to Sorrento Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 141.16M. This represents a change of -70.20% compared to the average of 473.75M of the last 4 quarters.
The mean historical Enterprise Value of Sorrento Therapeutics, Inc. over the last ten years is 585.54M. The current 141.16M Enterprise Value has changed 2.31% with respect to the historical average. Over the past ten years (40 quarters), SRNE's Enterprise Value was at its highest in in the September 2020 quarter at 2.95B. The Enterprise Value was at its lowest in in the September 2014 quarter at 96.80M.
Average
585.54M
Median
305.69M
Minimum
95.01M
Maximum
1.68B
Discovering the peaks and valleys of Sorrento Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 132.46%
Maximum Annual Enterprise Value = 1.68B
Minimum Annual Increase = -69.31%
Minimum Annual Enterprise Value = 95.01M
Year | Enterprise Value | Change |
---|---|---|
2022 | 482.38M | -69.31% |
2021 | 1.57B | -6.53% |
2020 | 1.68B | 126.25% |
2019 | 743.20M | 132.46% |
2018 | 319.72M | 27.99% |
2017 | 249.80M | 18.01% |
2016 | 211.68M | -27.42% |
2015 | 291.67M | 39.62% |
2014 | 208.90M | 119.88% |
2013 | 95.01M | 1.92% |
The current Enterprise Value of Sorrento Therapeutics, Inc. (SRNE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
1.25B
5-year avg
959.68M
10-year avg
585.54M
Sorrento Therapeutics, Inc.’s Enterprise Value is
Company | Enterprise Value | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Sorrento Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Sorrento Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Sorrento Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Sorrento Therapeutics, Inc. (SRNE)?
What is the 3-year average Enterprise Value for Sorrento Therapeutics, Inc. (SRNE)?
What is the 5-year average Enterprise Value for Sorrento Therapeutics, Inc. (SRNE)?
How does the current Enterprise Value for Sorrento Therapeutics, Inc. (SRNE) compare to its historical average?